Additionally, entacapone, a catechol-O-methyltransferase inhibitor used in Parkinson’s disease, was also identified as an FTO inhibitor, influencing metabolic homeostasis by selectively inhibiting FTO activity [99]. This evidence concerns the gene FTO and Parkinson disease.